GGrantIndex
Sort

53,477 grants matching addiction

Low-input profiling of brain-region and cell-type specific epigenomic dynamics to understand gene-environment interactions in opioid addiction

$732,324
Chang Lu · Virginia Polytechnic Inst And St Univ · R01 · FY2023 · DA

Identification of synthetic lethal interactors in pancreatic cancer

$732,247
Channing J Der · Univ Of North Carolina Chapel Hill · U01 · FY2016 · CA

Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts

$732,228
Warren K Bickel · Virginia Polytechnic Inst And St Univ · R01 · FY2012 · DA

Imaging sex differences in smoking-induced dopamine release via novel PET methods

$731,997
Evan D Morris · Yale University · R01 · FY2016 · DA

Drug Abuse Training Program

$731,894
Jacqueline F. McGinty · Medical University Of South Carolina · T32 · FY2019 · DA

sEH Inhibitors to Treat Neuropathic Pain

$731,876
Alan R Buckpitt · Eicosis, Llc · R44 · FY2016 · ES

Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine

$731,871
Sebastian Seiguer · Emocha Mobile Health, Inc. · R44 · FY2018 · DA

Research Support Core D: Clinical and Behavioral Services

$731,866
Ann K Avery · Case Western Reserve University · P30 · FY2023 · DA

Research Support Core D: Clinical and Behavioral Services

$731,866
Ann K Avery · Case Western Reserve University · P30 · FY2022 · DA

Research Support Core D: Clinical and Behavioral Services

$731,866
Ann K Avery · Case Western Reserve University · P30 · FY2024 · DA

Molecular mechanisms of memory maintenance and dysfunction in neural circuits

$731,684
Todd C Sacktor · Suny Downstate Medical Center · R01 · FY2019 · MH

A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care

$731,641
Michael Scott Gordon · Friends Research Institute, Inc. · R01 · FY2011 · DA

Addictions treatment organizational response to COVID-19: impact on disparities in quality of care

$731,602
Charles J Neighbors · New York University School Of Medicine · R01 · FY2023 · DA

Evaluation of Clinical Effectiveness, Cost, and Implementation Factors to Optimize Scalability of Treatment for Co-Occurring SUD and PTSD Among Teens

$731,580
Carla Kmett Danielson · Medical University Of South Carolina · R01 · FY2022 · DA

Methodology and measurement for examining short-term and long-term effects of e-cigarette and polysubstance use

$731,536
Yuh-Pey Anne Buu · University Of Texas Hlth Sci Ctr Houston · R01 · FY2020 · DA

Rapid response human testing of smokeless tobacco products

$731,510
Pamela I Clark · Univ Of Maryland, College Park · R01 · FY2014 · DA

PTSD and Addiction Disorder Screening and Treatment for Incarcerated Men

$731,468
Nancy Wolff · Rutgers, The State Univ Of N.J. · R01 · FY2011 · MH

Parallel Multimodal High-throughput screening to identify activators of the orexin receptors

$731,424
Theodore M Kamenecka · Scripps Florida · R01 · FY2020 · MH

Essential Fatty Acids In Psychiatric Disorders

$731,401
Joseph Hibbeln · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2020 · AA

Blood Donor Competence, Autonomy and Relatedness Enhancement (Blood Donor CARE)

$731,352
Christopher R France · Ohio University Athens · R01 · FY2017 · HL

Supporting Treatment Access and Recovery in Re-entry (STAR-R)

$731,275
David A Smelson · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · DA

Ending the HIV Epidemic: Peer-supported collaborative care for mental health and substance use disorder care integration into HIV care settings

$731,201
Oluwaseun Falade-Nwulia · Johns Hopkins University · R01 · FY2020 · DA

Neurobehavioral Determinants of Adolescent Substance Use and HIV/STD Behaviors

$731,183
Jungmeen Kim · Virginia Polytechnic Inst And St Univ · R01 · FY2013 · DA

Drug Dependence Clinical Research Program

$731,167
Reese T. Jones · University Of California, San Francisco · P30 · FY2018 · DA

Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse

$730,959
Joan Weinberger Berman · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · DA